Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121471 · ClinicalTrials.gov registry record · NA
Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)
A NA study, sponsored by Ohio State University.
- Completed
- Registry status
- NA
- Development phase
- 55
- Enrollment target
NCT01121471: Completed NA study, sponsored by Ohio State University.
NCT01121471 is a NA study that has completed, run by Ohio State University. The registered enrollment target is 55 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01121471, a NA study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).
Primary Outcome
significant change in plasma glucose AUC (0-3 h) from baseline to Week 16.
Interventions
- DIETARY_SUPPLEMENT Conjugated Linoleic Acid (CLA)
- DIETARY_SUPPLEMENT Safflower OIl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-11 |
| Phase | NA |
What the finished NCT01121471 record still lists
NCT01121471 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 55 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 2 interventions - of which Conjugated Linoleic Acid (CLA) is the first listed.
NCT01121471 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01121471 about?
NCT01121471 is a clinical study titled "Supplementation With Conjugated Linoleic Acid (CLA) as Complementary Therapy in the Management of Type 2 Diabetes Mellitus (Women's Diabetes Study)". The purpose of this study is to determine the role of CLA as a complementary therapy to improve body composition, glucose tolerance, fasting plasma glucose and insulin, and hemoglobinA1c (HbA1c) in subjects with type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT01121471?
This trial is currently completed. It is a NA study. The enrollment target is 55 participants. The study started on 2004-12. Estimated completion is 2006-11.
What interventions are being tested in trial NCT01121471?
The interventions under investigation include: Conjugated Linoleic Acid (CLA) (DIETARY_SUPPLEMENT), Safflower OIl (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01121471?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01121471's enrollment target sits among peer trials
55 1264th of 2000 higher than 733 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01638676 · 55 participants · Phase 1
A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
- NCT01906385 · 55 participants · Phase 1
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
- NCT03007030 · 55 participants · Phase 2
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- NCT03152058 · 55 participants · Phase 2
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia